Linked Life Data

16918421

Source:http://linkedlifedata.com/resource/pubmed/id/16918421

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2006-8-21
pubmed:abstractText
This review highlights recent advances in our understanding of intracellular mechanisms underlying programmed cell death in hepatic ischemia/reperfusion injury. A range of molecules have been tested with the intention to block the pathways of programmed cell death at different levels and to thereby enhance viability of the liver in surgical procedures including liver transplantation. Cellular death receptors, the mitochondrial pathway of apoptosis, p53, mitogen-activated protein kinases (MAPKs) and intracellular proteases all present potential targets for pharmaceutical agents to prevent ischemia induced cell death in the liver. Although evidence has been provided for effective inhibition of injury and improvement of survival by such agents, an optimal treatment strategy remains to be developed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1381-6128
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2911-21
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Blocking the path to death: anti-apoptotic molecules in ischemia/reperfusion injury of the liver.
pubmed:affiliation
Swiss Hepato-Pancreato-Biliary Centre, Department of Visceral and Transplantation Surgery, University Hospital of Zürich, Rämistrasse 100, 8091-Zürich, Switzerland.
pubmed:publicationType
Journal Article, Review